Testing a cancer medicine for advanced solid tumors with HSV
Part of Cancer clinical trials.
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old and can give signed informed consent.
- Your cancer is an advanced “solid tumor,” and it has come back, stopped responding, or you have no standard option.
- You have at least one injectable skin or lymph node tumor spot (at least 15 mm).
- You test positive for herpes simplex virus (HSV).
- Your overall health is good enough for study treatment (ECOG 0 or 1, and key blood/oxygen measures meet limits).
- You can wait the required time after prior treatments, and you can follow birth-control and infection-safety rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
This Phase 2 study tests a drug called VG161 given by injection into liver tumors, either alone or together with nivolumab. It aims to see how well it works and whether it is safe for people with advanced hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).
This trial tests a new drug, VG2025, given through a vein for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the tumors.
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.